AMPE

15-12G - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

25 - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

ENGLEWOOD, Colo., April 3, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company" or "Ampio") today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 27, 2024 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. Further discussion is included in footnote 2 of the Company's financial statements included in the Company's Annual Report on Form 10-K. This announcement is

Ampio Pharmaceuticals (AMEX:AMPE) reported quarterly losses of $(2.48) per share. This is a 31.11 percent increase over losses of $(3.60) per share from the same period last year.

8-K - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

The Company today notified the NYSE American of its intention to voluntarily delist its shares of common stock from the NYSE American. 

ENGLEWOOD, Colo., March 25, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company" or "Ampio") today announced that its Board of Directors determined to voluntarily delist its common stock from the NYSE American and deregister its common stock in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"). The Company today notified the NYSE American of its intention to voluntarily delist its shares of common stock from the NYSE American. The Company intends to file a Form 25 with

EFFECT - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

Gainers Societal CDMO (NASDAQ:SCTL) stock rose 132.6% to $1.07 during Thursday's regular session. The company's market cap stands at $112.1 million. Enveric Biosciences (NASDAQ:ENVB) shares increased by 132.25% to $1.93. The market value of their outstanding shares is at $5.2 million. Envoy Medical (NASDAQ:COCH) stock rose 47.29% to $5.17. The market value of their outstanding shares is at $101.0 million. Tivic Health Systems (NASDAQ:TIVC) shares moved upwards by 30.39% to $1.63. The market value of their outstanding shares is at $2.3 million. Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 29.68% to $7.34. The company's market cap stands at $644.5 million. The company's, Q4 e

Gainers Enveric Biosciences (NASDAQ:ENVB) stock rose 162.3% to $2.18 during Thursday's pre-market session. The company's market cap stands at $5.9 million. Societal CDMO (NASDAQ:SCTL) shares moved upwards by 134.78% to $1.08. The company's market cap stands at $113.1 million. NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 45.11% to $7.43. The company's market cap stands at $36.4 million. OneMedNet (NASDAQ:ONMD) stock moved upwards by 28.97% to $0.89. The market value of their outstanding shares is at $28.7 million. Establishment Labs Hldgs (NASDAQ:ESTA) stock increased by 21.91% to $46.89. The market value of their outstanding shares is at $1.2 billion. As per the press relea

Gainers IGC Pharma (AMEX:IGC) shares moved upwards by 14.6% to $0.4 during Wednesday's after-market session. The market value of their outstanding shares is at $25.4 million. Establishment Labs Hldgs (NASDAQ:ESTA) shares rose 14.43% to $44.01. The market value of their outstanding shares is at $1.1 billion. The company's, Q4 earnings came out today. Voyager Therapeutics (NASDAQ:VYGR) shares moved upwards by 11.44% to $10.0. The market value of their outstanding shares is at $555.6 million. As per the press release, Q4 earnings came out today. Natera (NASDAQ:NTRA) shares moved upwards by 9.73% to $84.0. The company's market cap stands at $10.0 billion. As per the press release, Q4 earning

- SEC Filing On February 26, 2024, Ampio Pharmaceuticals, Inc. (the "Company") provided a notice to H.C. Wainwright & Co., LLC to terminate that certain At The Marketing Offering Agreement, dated September 18, 2023, by and between the Company and H.C. Wainwright & Co., LLC (the "ATM Agreement"), establishing an at-the-market equity distribution program for the offer and sale from time to time shares of the Company's common stock, par value $0.0001. In accordance with the ATM Agreement, the termination will be effective March 6, 2024. In connection with the termination of the ATM Agreement, the Company filed on February 28, 2024 a post-effective amendment to its Registration Statement on Form

8-K - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

S-8 POS - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

S-8 POS - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

POS AM - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

RW - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

8-K - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

The Company's management and the Board are currently assessing both internal and external options. 

ENGLEWOOD, Colo., Feb. 14, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio's only product development opportunity.  Ampio reported that the efficacy results of these studies do not support an Investigational New Drug ("IND") submission which was anticipated in early 2025. Specifically, whereas previous smaller studies had demonstrated that OA-201 showed efficacy versus saline control to reduce p

8-K - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

424B5 - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

424B5 - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)

8-K - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)